This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Related articles in Am J Pathol Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guedez, L. Articles by Stetler-Stevenson, W. G. Search for Related Content PubMed PubMed Citation Articles by Guedez, L. Articles by Stetler-Stevenson, W. G.

(American Journal of Pathology. 2003;162:1431-1439.)
© 2003 American Society for Investigative Pathology

Technical Advances

Quantitative Assessment of Angiogenic Responses by the Directed in Vivo Angiogenesis Assay

Liliana Guedez^*, Alexandra M. Rivera^*, Rita Salloum^*, Megan L. Miller, Jared J. Diegmueller, Peter M. Bungay and William G. Stetler-Stevenson^*

From the Extracellular Matrix Section,^*Laboratory of Pathology, and the Vascular Biology Faculty,Center for Cancer Research, National Cancer Institute; and the Division of Bioengineering and Physical Science,Office of Research Services, National Institutes of Health, Bethesda, Maryland

One of the major problems in angiogenesis research remains the lack of suitable methods for quantifying the angiogenic response in vivo. We describe the development and application of the directed in vivo angiogenesis assay (DIVAA) and demonstrated that it is reproducible and quantitative. This assay consists of subcutaneous implantation of semiclosed silicone cylinders (angioreactors) into nude mice. Angioreactors are filled with only 18 µl of extracellular matrix premixed with or without angiogenic factors. Vascularization within angioreactors is quantified by the intravenous injection of fluorescein isothiocyanate (FITC)-dextran before their recovery, followed by spectrofluorimetry. Angioreactors examined by immunofluorescence show cells and invading angiogenic vessels at different developmental stages. The minimally detectable angiogenic response requires 9 days after implantation and 50 ng/ml (P < 0.01) of either fibroblast growth factor-2 or vascular endothelial growth factor. Characterization of this assay system demonstrates that the FITC-labeled dextran quantitation is highly reproducible and that levels of FITC-dextran are not significantly influenced by vascular permeability. DIVAA allows accurate dose-response analysis and identification of effective doses of angiogenesis-modulating factors in vivo. TNP-470 potently inhibits angiogenesis (EC₅₀ = 88 pmol/L) induced by 500 ng/ml of fibroblast growth factor-2. This inhibition correlates with decreased endothelial cell invasion. DIVAA efficiently detects differences in anti-angiogenic potencies of thrombospondin-1 peptides (25 µmol/L) and demonstrates a partial inhibition of angiogenesis (40%) in a matrix metalloprotease (MMP)-2-deficient mouse compared with that in wild-type animals. Zymography of angioreactors from MMP-deficient and control animals reveals quantitative changes in MMP expression. These results support DIVAA as an assay to compare potencies of angiogenic factors or inhibitors, and for profiling molecular markers of angiogenesis in vivo.

Related articles in Am J Pathol:

This Month in AJP

Am J Pathol 2003 162: 1391-1392. [Full Text]  

This article has been cited by other articles:

				M. Chrzanowska-Wodnicka, A. E. Kraus, D. Gale, G. C. White II, and J. VanSluys Defective angiogenesis, endothelial migration, proliferation, and MAPK signaling in Rap1b-deficient mice Blood, March 1, 2008; 111(5): 2647 - 2656. [Abstract] [Full Text] [PDF]

				S. Liu, H. Wang, B. M. Currie, A. Molinolo, H. J. Leung, M. Moayeri, J. R. Basile, R. W. Alfano, J. S. Gutkind, A. E. Frankel, et al. Matrix Metalloproteinase-activated Anthrax Lethal Toxin Demonstrates High Potency in Targeting Tumor Vasculature J. Biol. Chem., January 4, 2008; 283(1): 529 - 540. [Abstract] [Full Text] [PDF]

				L. Yin, K.-i. Morishige, T. Takahashi, K. Hashimoto, S. Ogata, S. Tsutsumi, K. Takata, T. Ohta, J. Kawagoe, K. Takahashi, et al. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo Mol. Cancer Ther., May 1, 2007; 6(5): 1517 - 1525. [Abstract] [Full Text] [PDF]

				J. R. Basile, K. Holmbeck, T. H. Bugge, and J. S. Gutkind MT1-MMP Controls Tumor-induced Angiogenesis through the Release of Semaphorin 4D J. Biol. Chem., March 2, 2007; 282(9): 6899 - 6905. [Abstract] [Full Text] [PDF]

				H. Caldas, J. R. Fangusaro, D. R. Boue, M. P. Holloway, and R. A. Altura Dissecting the role of endothelial SURVIVIN {Delta}Ex3 in angiogenesis Blood, February 15, 2007; 109(4): 1479 - 1489. [Abstract] [Full Text] [PDF]

				P. M. Cummins, N. von Offenberg Sweeney, M. T. Killeen, Y. A. Birney, E. M. Redmond, and P. A. Cahill Cyclic strain-mediated matrix metalloproteinase regulation within the vascular endothelium: a force to be reckoned with Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H28 - H42. [Abstract] [Full Text] [PDF]

				D.-W. Seo, H. Li, C.-K. Qu, J. Oh, Y.-S. Kim, T. Diaz, B. Wei, J.-W. Han, and W. G. Stetler-Stevenson Shp-1 Mediates the Antiproliferative Activity of Tissue Inhibitor of Metalloproteinase-2 in Human Microvascular Endothelial Cells J. Biol. Chem., February 10, 2006; 281(6): 3711 - 3721. [Abstract] [Full Text] [PDF]

				E. Zudaire, A. Martinez, M. Garayoa, R. Pio, G. Kaur, M. R. Woolhiser, D. D. Metcalfe, W. A. Hook, R. P. Siraganian, T. A. Guise, et al. Adrenomedullin Is a Cross-Talk Molecule that Regulates Tumor and Mast Cell Function during Human Carcinogenesis Am. J. Pathol., January 1, 2006; 168(1): 280 - 291. [Abstract] [Full Text] [PDF]

				T. Wang, Y. Ward, L. Tian, R. Lake, L. Guedez, W. G. Stetler-Stevenson, and K. Kelly CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells Blood, April 1, 2005; 105(7): 2836 - 2844. [Abstract] [Full Text] [PDF]

				C. Bianco, L. Strizzi, A. Ebert, C. Chang, A. Rehman, N. Normanno, L. Guedez, R. Salloum, E. Ginsburg, Y. Sun, et al. Role of Human Cripto-1 in Tumor Angiogenesis J Natl Cancer Inst, January 19, 2005; 97(2): 132 - 141. [Abstract] [Full Text] [PDF]

				T.-H. Chun, F. Sabeh, I. Ota, H. Murphy, K. T. McDonagh, K. Holmbeck, H. Birkedal-Hansen, E. D. Allen, and S. J. Weiss MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix J. Cell Biol., November 22, 2004; 167(4): 757 - 767. [Abstract] [Full Text] [PDF]

				A. Martinez, E. Zudaire, S. Portal-Nunez, L. Guedez, S. K. Libutti, W. G. Stetler-Stevenson, and F. Cuttitta Proadrenomedullin NH2-Terminal 20 Peptide Is a Potent Angiogenic Factor, and Its Inhibition Results in Reduction of Tumor Growth Cancer Res., September 15, 2004; 64(18): 6489 - 6494. [Abstract] [Full Text] [PDF]

				F. Mor, F. J. Quintana, and I. R. Cohen Angiogenesis-Inflammation Cross-Talk: Vascular Endothelial Growth Factor Is Secreted by Activated T Cells and Induces Th1 Polarization J. Immunol., April 1, 2004; 172(7): 4618 - 4623. [Abstract] [Full Text] [PDF]

				M. L. Wahl, T. L. Moser, and S. V. Pizzo Angiostatin and Anti-angiogenic Therapy in Human Disease Recent Prog. Horm. Res., January 1, 2004; 59(1): 73 - 104. [Abstract] [Full Text]